Contributions
Abstract: 58
Type: Scientific Session
Abstract Category: Clinical aspects of MS - Epidemiology
Background: The prevalence of familial multiple sclerosis (FMS) has been estimated as 10% of multiple sclerosis (MS) patients. There have been few studies comparing FMS patients as a group with sporadic MS (SMS).
Goal: To compare demographic and clinical characteristics of multiple sclerosis between familial and sporadic forms.
Methods: Worldwide multicenter study that included patients from 32 MS centers from January 2005 to April 2016. Data was source from MSBASE Registry. Patients were divided into two groups: FMS and SMS. Patients were considered as FMS if they had at least one relative (first, second or third degree diagnosed with MS; otherwise, patients were considered SMS). We compared demographic and clinical characteristics between the two groups.
Results: 17739 patients from the 32 centres were analyzed, 1194 had FMS (7.25%). No differences were found regarding gender or MS course, but a lower age at onset was seen in FMS (28.1 vs 29.5, p=0,0009). The diagnosis also ocurred earlier in FMS (32.4 vs 33.2, p=0,03). FMS patients had a higher number of relapses (1.69 VS 1.32, p< 0.0001) and a higher annualized relapse rate (ARR) (0.34, 95%IC=0.32-0.35 vs 0.26, 95%IC=0.26-0.27, p< 0,0001) than SMS within the 5 first years from onset. Time between the two first relapses was shorter in FMS, hazard ratio [HR] 1.20 (95%IC=1.13-1.29, p< 0,001), time to progression from relapsing remitting MS to secondary progressive MS was also shorter (hazard ratio [HR] 1.32 (95%IC=1.15-1.51), p< 0,001) as was time to reach an EDSS of 4.0 [HR] 1.27 (95%IC=1.01-1.61), p=0,047).
Conclusion: We observed an earlier onset but also a more severe course in the familial MS compared to sporadic MS
Disclosure: - Sara Eichau: Consulting and/or speaking fees (Biogen, Merck Serono, Novartis, Roche, Sanofi and Teva)
- Tim Spelman did not declare any competing interests.
- Rocío López Ruiz did not declare any competing interests.
- Pierre Duquette served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme.
- Alexandre Prat did not declare any competing interests.
- Marc Girard received consulting fees from Teva Canada Innovation, Biogen, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD . He has also received a research grant from Canadian Institutes of Health Research.
- Guillermo Izquierdo received speaking honoraria from Biogen, Novartis, Sanofi, Merck, Roche, Almirall and Teva.
- Carmen Sirbu-Adella did not declare any competing interests.
- Tatjana Petkovska-Boskova did not declare any competing interests.
- Juan Ignacio Rojas did not declare any competing interests.
- Yara Fragoso received honoraria as a consultant on scientific advisory boards by Novartis, Teva, Roche and Sanofi-Aventis and compensation for travel from Novartis, Biogen, Sanofi Aventis, Teva, Roche and Merck.
- Tamara Castillo Triviño did not declare any competing interests.
- Ricardo Fernández Bolaños did not declare any competing interests.
- Norbert Vella did not declare any competing interests.
- Celia Oreja-Guevara did not declare any competing interests.
- Elisabetta Cartechini did not declare any competing interests.
- José Luis Sánchez Menoyo did not declare any competing interests.
- Eugenio Pucci served on scientific advisory boards for Merck, Genzyme and Biogen; he has received honoraria and travel grants from Sanofi Aventis, Novartis, Biogen, Merck, Genzyme and Teva; he has received travel grants and equipment from "Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche".
- Diana Ferraro received travel grants and/or speaker honoraria from Merck, TEVA,Novartis, Biogen and Sanofi-Genzyme.
- Patrizia Sola served on scientific advisory boards for Biogen Idec and TEVA, she has received funding for travel and speaker honoraria from Biogen Idec, Merck , Teva, Sanofi Genzyme, Novartis and Bayer and research grants for her Institution from Bayer, Biogen, Merck , Novartis, Sanofi, Teva.
- Gerardo Iuliano had travel/accommodations/meeting expenses funded by Bayer Schering, Biogen, Merck , Novartis, Sanofi Aventis, and Teva.
- Vincent Van Pesch has received travel grants from Biogen, Bayer Schering, Genzyme, Merck, Teva, Roche and Novartis Pharma. His institution receives honoraria for consultancy and lectures from Biogen, Bayer Schering, Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Novartis Pharma, Roche and Bayer Schering.
- Serkan Ozakbas did not declare any competing interests.
- Raed Alroughani did not declare any competing interests.
- Maria Trojano received speaker honoraria from Biogen-Idec, Bayer-Schering, Sanofi Aventis, Merck, Teva , Novartis and Almirall; has received research grants for her Institution from Biogen-Idec, Merck, and Novartis.
- Pietro Iaffaldano did not declare any competing interests.
- Marco Onofrj did not declare any competing interests.
- Cavit Boz received conference travel support from Biogen, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.
- Tomas Kalincik served on scientific advisory boards for Roche, Genzyme-Sanofi, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen.
- Murat Terzi received travel grants from Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.
-H Butzkueven has served on scientific advisory boards for Biogen, Roche, Merck, Novartis, Teva and Sanofi and has received conference travel support from Novartis, Biogen and Merck. He serves on steering committees for trials conducted by Merck, Biogen and Novartis, and has received research support from Novartis, Biogen, NHMRC Australia, MS Research Australia and the UK MS Trust.
Abstract: 58
Type: Scientific Session
Abstract Category: Clinical aspects of MS - Epidemiology
Background: The prevalence of familial multiple sclerosis (FMS) has been estimated as 10% of multiple sclerosis (MS) patients. There have been few studies comparing FMS patients as a group with sporadic MS (SMS).
Goal: To compare demographic and clinical characteristics of multiple sclerosis between familial and sporadic forms.
Methods: Worldwide multicenter study that included patients from 32 MS centers from January 2005 to April 2016. Data was source from MSBASE Registry. Patients were divided into two groups: FMS and SMS. Patients were considered as FMS if they had at least one relative (first, second or third degree diagnosed with MS; otherwise, patients were considered SMS). We compared demographic and clinical characteristics between the two groups.
Results: 17739 patients from the 32 centres were analyzed, 1194 had FMS (7.25%). No differences were found regarding gender or MS course, but a lower age at onset was seen in FMS (28.1 vs 29.5, p=0,0009). The diagnosis also ocurred earlier in FMS (32.4 vs 33.2, p=0,03). FMS patients had a higher number of relapses (1.69 VS 1.32, p< 0.0001) and a higher annualized relapse rate (ARR) (0.34, 95%IC=0.32-0.35 vs 0.26, 95%IC=0.26-0.27, p< 0,0001) than SMS within the 5 first years from onset. Time between the two first relapses was shorter in FMS, hazard ratio [HR] 1.20 (95%IC=1.13-1.29, p< 0,001), time to progression from relapsing remitting MS to secondary progressive MS was also shorter (hazard ratio [HR] 1.32 (95%IC=1.15-1.51), p< 0,001) as was time to reach an EDSS of 4.0 [HR] 1.27 (95%IC=1.01-1.61), p=0,047).
Conclusion: We observed an earlier onset but also a more severe course in the familial MS compared to sporadic MS
Disclosure: - Sara Eichau: Consulting and/or speaking fees (Biogen, Merck Serono, Novartis, Roche, Sanofi and Teva)
- Tim Spelman did not declare any competing interests.
- Rocío López Ruiz did not declare any competing interests.
- Pierre Duquette served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme.
- Alexandre Prat did not declare any competing interests.
- Marc Girard received consulting fees from Teva Canada Innovation, Biogen, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD . He has also received a research grant from Canadian Institutes of Health Research.
- Guillermo Izquierdo received speaking honoraria from Biogen, Novartis, Sanofi, Merck, Roche, Almirall and Teva.
- Carmen Sirbu-Adella did not declare any competing interests.
- Tatjana Petkovska-Boskova did not declare any competing interests.
- Juan Ignacio Rojas did not declare any competing interests.
- Yara Fragoso received honoraria as a consultant on scientific advisory boards by Novartis, Teva, Roche and Sanofi-Aventis and compensation for travel from Novartis, Biogen, Sanofi Aventis, Teva, Roche and Merck.
- Tamara Castillo Triviño did not declare any competing interests.
- Ricardo Fernández Bolaños did not declare any competing interests.
- Norbert Vella did not declare any competing interests.
- Celia Oreja-Guevara did not declare any competing interests.
- Elisabetta Cartechini did not declare any competing interests.
- José Luis Sánchez Menoyo did not declare any competing interests.
- Eugenio Pucci served on scientific advisory boards for Merck, Genzyme and Biogen; he has received honoraria and travel grants from Sanofi Aventis, Novartis, Biogen, Merck, Genzyme and Teva; he has received travel grants and equipment from "Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche".
- Diana Ferraro received travel grants and/or speaker honoraria from Merck, TEVA,Novartis, Biogen and Sanofi-Genzyme.
- Patrizia Sola served on scientific advisory boards for Biogen Idec and TEVA, she has received funding for travel and speaker honoraria from Biogen Idec, Merck , Teva, Sanofi Genzyme, Novartis and Bayer and research grants for her Institution from Bayer, Biogen, Merck , Novartis, Sanofi, Teva.
- Gerardo Iuliano had travel/accommodations/meeting expenses funded by Bayer Schering, Biogen, Merck , Novartis, Sanofi Aventis, and Teva.
- Vincent Van Pesch has received travel grants from Biogen, Bayer Schering, Genzyme, Merck, Teva, Roche and Novartis Pharma. His institution receives honoraria for consultancy and lectures from Biogen, Bayer Schering, Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Novartis Pharma, Roche and Bayer Schering.
- Serkan Ozakbas did not declare any competing interests.
- Raed Alroughani did not declare any competing interests.
- Maria Trojano received speaker honoraria from Biogen-Idec, Bayer-Schering, Sanofi Aventis, Merck, Teva , Novartis and Almirall; has received research grants for her Institution from Biogen-Idec, Merck, and Novartis.
- Pietro Iaffaldano did not declare any competing interests.
- Marco Onofrj did not declare any competing interests.
- Cavit Boz received conference travel support from Biogen, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.
- Tomas Kalincik served on scientific advisory boards for Roche, Genzyme-Sanofi, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen.
- Murat Terzi received travel grants from Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.
-H Butzkueven has served on scientific advisory boards for Biogen, Roche, Merck, Novartis, Teva and Sanofi and has received conference travel support from Novartis, Biogen and Merck. He serves on steering committees for trials conducted by Merck, Biogen and Novartis, and has received research support from Novartis, Biogen, NHMRC Australia, MS Research Australia and the UK MS Trust.